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Abstract
Background & Aims—Aldehydes that are produced following the breakdown of ethanol
(acetaldehyde) and lipid peroxidation of membranes (malondialdehyde) have been shown to bind
(adduct) proteins. Additionally, these two aldehydes can combine (MAA) on non-syngeneic and
syngeneic proteins to initiate numerous immune responses to the unmodified part of the protein in
the absence of an adjuvant. Therefore, these studies provide a potential mechanism for the
development of antigen-specific immune responses resulting in liver damage should syngeneic
liver proteins be adducted with MAA.
Methods—This study sought to test whether MAA modified syngeneic liver cytosolic proteins
administered daily in the absence of adjuvant into C57BL/6 mice abrogates tolerance to initiate a
MAA induced autoimmune-like hepatitis (MIAH).
Results—In mice immunized with MAA modified cytosols there was an increase in liver
damage as assessed by AST/ALT levels that correlated with liver pathology scores and the
presence of the pro-fibrotic factors; smooth muscle actin (SMA), TGF-β, and collagen. IgG
antibodies and T-cell proliferative responses specific for cytosolic proteins were also detected.
Pro-inflammatory cytokines were produced in the livers of animals exposed to MAA-modified
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cytosols. Finally, transfer of immunized T-cells to naïve animals caused biochemical and
histological evidence of liver damage.
Conclusions—These data demonstrate that a disease with an autoimmune-like pathophysiology
can be generated in this animal model using soluble MAA modified syngeneic liver cytosols as the
immunogen. These studies provide insight into potential mechanism(s) that the metabolites of
alcohol may play in contributing to the onset of an autoimmune-like disease in ALD patients.
Introduction
A number of different studies suggest that the onset of alcoholic liver disease (ALD) is
initiated in part by immune mechanisms. The detection of circulating antibodies and
lymphocytes with specificity to hepatic antigens in patients with ALD strongly supports this
hypothesis (Cook, 1998; Duryee et al., 2004b; Laskin et al., 1990; Paronetto, 1993).
However, the mechanism(s) by which proteins from the liver break immunologic tolerance
and induce these autoimmune responses have not been identified. Studies have shown that
aldehyde modified proteins are present in the tissue of humans and animals consuming
ethanol. Also, the modification of proteins with aldehydes makes them antigenic (Israel et
al., 1986; Lin et al., 1990; Niemela et al., 1991; Terabayashi and Kolber, 1990).
Reports from our laboratories have demonstrated the development of antibodies and T cell
responses to exogenous proteins modified with the combination of metabolically-derived
aldehydes (MAlondialdehyde and Acetaldehyde) or MAA (Tuma et al., 1996; Willis et al.,
2003; Xu et al., 1997) in the absence of any adjuvant (Thiele et al., 1998), making the
immunogenicity of those biotransformed proteins relevant. Circulating antibodies to the
MAA adduct have been detected in the serum of both humans and rats chronically
consuming alcohol (Rolla et al., 2000; Xu et al., 1998). In humans, anti-MAA antibodies
have correlated both with the presence and severity of ALD. Additionally, alcohol fed rats
generated antibodies that responded to unmodified liver self-proteins, suggesting that MAA
adducts induce an anti-self immune response (Xu et al., 1998).
A number of animal models of autoimmune hepatitis have been developed in order to study
the underlying mechanisms of disease initiation (Lohse et al., 1990; Peters, 2002; Tiegs,
1997). However, most rely on the use of both strong adjuvants and high doses of antigen to
initiate autoimmunity (Howell and Yoder, 1994; Kohda et al., 1990; Tiegs, 1997). For
example, chemical modifications of self proteins have been shown to generate an
autoimmune humoral response to the modified and carrier protein when administered in
adjuvants (Abraham et al., 1997; Abraham et al., 1995; Thiele et al., 1998). Additionally,
lipid peroxidation products given with adjuvants have been shown to break tolerance to
syngeneic proteins and generate T cell reponses (Wallberg et al., 2007; Wuttge et al., 1999).
There is a wide spectrum of alcohol-related pathology in humans and animals including;
hepatitis, steatosis, non-specific steatohepatitis, apoptosis, and centrilobular, periportal and
pericellular fibrosis (French and Tsukamoto, 1989; Lieber and DeCarli, 1982; Song et al.,
2002). However, no one animal model has totally mimicked the classical pattern of alcoholic
hepatitis observed in humans. Importantly, these animal models have been invaluable in
evaluating the individual (LPS, fatty liver, oxidative stress, etc.) potential pathogenic
mechanisms that potentially contribute to the development and/or progression of ALD.
Therefore, this study elucidates the contribution of aldehdye-modified proteins in initiating
immune responses that may play a role in this process. In these studies, mice were
immunized in the absence or adjuvants with MAA-modified syngeneic proteins. A daily
course of immunizations was initiated in order to mimic the exposure that an alcoholic
would encounter over time to these aldehyde-modified proteins. Importantly, these studies
were developed in order to determine whether liver self-proteins modified with aldehydes
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can break tolerance in the absence of adjuvant and provide a model to study the immune
responses involved in ALD.
Materials and Methods
Animals
Six week old female C57BL/6 mice were obtained from Charles River Laboratories
(Wilmington, MA) and maintained on a Purina chow diet. All animals were allowed free
access to their food and/or water up to 1 hour prior to sacrifice. All procedures were
approved by the Animal Subcommittee of the Omaha VA Medical Center, and are in
accordance with the National Institutes of Health Guidelines on the Use of Laboratory
Animals.
Preparation of Malondialdehyde-Acetaldehyde Modified S100 (S100-MAA)
Syngeneic C57BL/6 mice were sacrificed daily, livers removed, and a S100 cytosolic
fraction prepared according to the method of Lohse et al (Lohse et al., 1990). These
materials were prepared daily in order to retain the antigenicity of the liver specific proteins
(LSPs) as previously described (Lohse et al., 1998). Protein concentration of the S100
fraction was determined using a BCA Protein Assay kit from Pierce (Rockford, IL). Daily
modifications of the S100 fraction with MAA was performed by incubating 4mM
malondialdehyde and 1mM acetaldehyde in 0.1 M phosphate buffer (PB) with 2 milligrams
of S100 at 37°C overnight (Tuma et al., 1996). These concentrations of aldehydes, while not
physiological, were chosen to modify the protein with MAA in the shortest possible time to
maintain protein immunogenicity (Lohse et al., 1998). Importantly, these concentrations of
AA and MDA resulted in the modification of syngeneic liver cytosols to the same level as
using physiological concentrations for a longer period of time. Therefore, the adducted
proteins should be biologically relevant. In order to guarantee modification of cytosolic
proteins with MAA had occurred, immuno-blot analysis used, and a polyclonal rabbit anti-
MAA antibody as the probe (Xu et al., 1997). Also, fluorescence for the dihydropyridine
structure (2:1 MAA) was detected using a spectrophotometer at 398 nm (excitation) and 460
nm (emission) and used in these studies. All samples were prepared under endotoxin-free
conditions and were determined to be endotoxin-free using the Limulus Amebocyte Lysate
assay from BioWhittaker (Walkersville, MD).
MAA Induced Autoimmune Hepatitis (MIAH)
Induction of MAA induced autoimmune hepatitis (MIAH) was performed by daily
intraperitoneal immunizations of 0.1M phosphate buffer (PB), 100 μg of S100 or 100 μg
S100 modified with MAA (S100-MAA) for 3 weeks. Intraperitoneal injection was chosen as
drainage should occur through the peritoneal lymph nodes and most likely mimic the
mechanism of removal of liver syngeneic proteins following tissue destruction in ALD. The
liver, spleen, and serum were removed following the last immunization.
Histology
Livers extracted from PB, S100 or S100-MAA immunized mice were placed in 10%
formalin PBS and embedded in paraffin. Sections were stained with hematoxylin/eosin and
blindly scored by a pathologist. Chronic hepatitis was graded using the Ludwig and Batts
scale from 0-4 (Batts and Ludwig, 1995).
AST/ALT Levels
Serum from animals immunized with PB, S100, or S100-MAA were collected by retro-
orbital bleeding just prior to immunization and at the time of sacrifice. Animals receiving
Thiele et al. Page 3













PB immunizations were used as controls to determine hemolysis in the serum, and these
values were subtracted from the test values. Alanine Aminotransferase (ALT) and aspartate
aminotransferase (AST) were measured for liver injury using colorimetric assay kits from
Bioquant (San Diego, CA).
Serum Antibody Levels to S100
A direct ELISA was used to determine the circulating antibody titers to the S100 cytosolic
fraction. Briefly, S100 or S100-MAA were coated onto (Immulon IV, Dynatech, Chantilly,
VA) ELISA plates at 2 μg/well in the presence of bicarbonate buffer, pH 9.6 and incubated
overnight at 37°C. Plates were washed, blocked using 2% Casein for 30 minutes, and serum
incubated at different dilutions on the plate for 1 hour at room temperature. The plates were
then washed and horse-radish peroxidase (HRP) labeled rabbit anti-mouse IgG (H&L)
antibody added (Sigma Chemical, Co, St. Louis, MO), incubated for 30 minutes, and
developed using TMB substrate. Absorbance was detected after stopping the reaction using
2N H2SO4 and reading at 450 nm using an MRX II Microplate Reader (Dynatech, Chantilly,
VA). Data were analyzed using Revelations Software from Dynatech, and expressed in pg/
ml using mouse IgG as a standard curve. Serum from PB immunized mice was used as
controls and values subtracted from the test samples. In order begin accessing the specific
proteins involved in the antibody response, S100 or S100-MAA were subjected to Western
Blot technique. Briefly, S100 or S100-MAA were resolved under reducing conditions by
SDS-PAGE on 10% gels and blotted onto Immun-Blot™ PVDF membrane (Bio-Rad,
Hercules, CA). PVDF membranes were blocked in milk and then incubated with serum from
mice immunized with S100-MAA. An alkaline phosphatase goat anti-mouse IgG (H&L)
secondary antibody (Jackson Immuno Research Laboratories, Inc., West Grove, PA) was
incubated and detected using BCIP/NBT substrate (Sigma Chemical Co., St. Louis, MO).
Proliferative responses to S100
To determine proliferative responses of T-cells from PB, S100 or S100-MAA immunized
mice, antigens (S100 or S100 MAA) were added to 96-well flat bottom plates at
concentrations ranging from 3.125 to 100 μg/ml. Spleen cells from mice in each of the
groups were added at a concentration of (1 × 105 cells/well) and incubated for 48 hours at
37°C in 5% CO2, pulsed with 1.0 μCi/well of [3H] thymidine (GE Healthcare, Piscataway,
NJ) for 16 hours, and harvested on a 96-well harvester (Tomtec, Orange, CO). Filter paper
containing the incorporated thymidine was placed in scintillation fluid and counted on a
1450 Microbeta Scintillation Counter (Perkin Elmer Life Sciences, Waltham, MA). Whole
spleen cell preparations were utilized as both T cells and a source of antigen presenting cells
(Dendritic cells and macrophages) are present. T cell proliferations were evaluated by
subtracting background levels (BKG) from naïve mice from PB and test samples. Data was
expressed as stimulation index (SI) using the following formula:
Passive Transfer of T-cells
In order to determine if cells of the immune system are involved in the detrimental effects of
S100-MAA immunization, spleenocytes were isolated from PB, S100, and S100-MAA
immunized animals. Briefly, spleens were removed, mechanically disrupted, single cell
suspensions prepared, adjusted to 5 × 106 cells/ml and stimulated for 48 hours with
concanavalin A (Con A) to stimulate T cell proliferation. These activated cells were washed
3 times with PBS to remove Con A, and transferred into naïve animals via i.p. injection
weekly for three weeks. Damage was assessed by serum AST levels and pathology scores.
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Livers from PB, S100 or S100-MAA immunized mice were removed and homogenized as
outlined in previous studies (Fairweather et al., 2003; Njoku et al., 2005). Homogenates
were tested for cytokine levels using the following ELISA kits: IL-1β, TNF-α, and IFN-γ
from BD Biosciences (San Diego, CA). Secretion levels are expressed in pg/ml extrapolated
from a standard curve supplied by the manufacturer and subtracted from PB animal cytokine
levels. Absorbance was detected at 450 nm using an MRX II Microplate Reader (Dynatech,
Chantilly, VA) and data analyzed using Revelations Software from Dynatech.
Smooth Muscle Actin and TGF-β Staining
Paraffin embedded sections were cut and subjected to immunohistochemical staining for the
increased presence of smooth muscle actin (SMA) and TGF-β. Briefly, following hydration
of the samples, antigen retrieval was performed using epitope retrieval buffer from Bethyl as
per the protocol (Bethyl Laboratories, Inc, Montgomery, TX). Sections were then incubated
with a monoclonal anti-actin, smooth muscle antibody (Sigma, St. Louis, MO), blocked in
peroxide, and incubated with an HRP goat anti-mouse IgG (Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA). DAB substrate was used as the detection reagent and
sections counterstained with hematoxylin.
For the TGF-β samples, antigen retrieval was not performed as it was not necessary for this
antigen. Sections were incubated with a rabbit anti-mouse TGF-β antibody (Santa Cruz
Biotech, Santa Cruz, CA), blocked in peroxide, and incubated with an HRP goat anti-rabbit
antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). DAB substrate
was used as the detection reagent and sections counterstained with hematoxylin. Slides were
analyzed using a Nikon Eclipse 80i at 200X power and Nis-Elements 3.0 software (Nikon,
Melville, NY).
Sirius Red Staining
Paraffin embedded liver tissue were cut and subjected to Sirius Red/fast green staining.
Briefly, slides were incubated in 0.1% fast green for 10 minutes and washed in acidified
water. Slides were then placed in pico-sirius red for 1 hour, followed by washing in acidified
water, rinsed in water, and dehydrated with ethanol. Slides were analyzed using a Nikon
Eclipse 80i at 200X power and Nis-Elements 3.0 software (Nikon, Melville, NY).
Results
In order to determine if MAA modified liver cytosol would cause significant liver damage
livers from mice immunized with PB, S100 or S100-MAA were removed, placed in
formalin, sectioned, and stained with H & E. Slides were scored using the Ludwig and Batts
scale of liver damage as described in Materials and Methods. Figure 1 (panel C) (a
representation of 5 other slides) demonstrates infiltration and liver damage compared to the
S100 (panel B) or PB animals (panel A). These sections were scored in a blinded fashion by
a pathologist and determined to have a 2 fold increase in the pathology score (P = 0.032) in
the S100-MAA immunized animals over the S100 controls (panel D).
To further assess liver damage in this model, serum was collected from mice immunized
with S100 or S100-MAA and tested for AST/ALT liver enzymes. As shown in Figure 2A
ALT levels were increased beginning at week 1 and through week 4 in the S100-MAA
immunized mice as compared to S100 immunized mice. In contrast AST levels (Figure 2B)
did not begin to increase in the serum of S100-MAA immunized mice until week 2, but they
continued their increase until the end of the study. PB mice had serum ALT and AST levels
< 50 IU/L throughout the study. At week 4, the enzyme levels were correlated to the
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pathology score and a correlation of 0.946 for AST and 0.988 for ALT was observed
indicating that as the liver enzymes increased so did the severity of the pathology score
(Figure 2C).
In some studies, organ specific autoimmune disease can be assessed by evaluating the levels
of IgG antibodies directed against liver self protein antigens. Examination of IgG specific
antibodies to S100 was done using serum from S100 or S100-MAA injected animals. As
shown in Figure 3 (panel A) serum antibodies to S100 were increased 5 fold (P < 0.001) in
the S100-MAA animals over control S100 animals. When these same sera were screened
using S100-MAA as the antigen, a dramatic increase in antibody concentration was
observed, indicating antibodies to the S100, MAA and S100-MAA epitopes were initiated.
These antibody concentrations were then compared to the pathology scores and found to
correlate (0.898, P=0.04) with the severity of the liver disease (Figure 3, panel B). To begin
examining the specific proteins to which these antibodies may bind serum from S100-MAA
immunized mice were evaluated using immunoblot procedures. Figure 4 shows serum
antibodies from S100-MAA mice reacting with bands between 60 and 28 kilo daltons.
Serum from PB and S100 immunized mice demonstrated no reactivity (data not shown).
In an effort to begin assessing whether cells of the immune system were involved in these
responses, spleen cells from PB, S100 or S100-MAA immunized animals were incubated
with S100 or S100-MAA antigens as described in the Materials and Methods. Proliferation
assays (Figure 5) showed that cells from the S100 immunized mice showed little or no
response as expressed by stimulation index (SI) to S100 or S100-MAA throughout the range
of antigens used. In contrast, cells from S100-MAA immunized mice showed SI’s that were
significantly elevated throughout the concentrations used compared to SI’s from S100
immunized animals whether the antigen was S100 or S100-MAA. However, it was apparent
that the response to S100-MAA was higher at all concentrations of antigens used. Spleen
cells from PB mice incubated with S100 or S100-MAA showed no stimulation in these
studies. These data suggest that the cellular response is enhanced as either; S100-MAA is
processed and presented more efficiently, or there is an additional response to MAA or
S100-MAA combination.
To determine if immune cells from immunized mice would elicit a response in vivo, passive
transfer experiments were performed. As shown in Table 1, spleen cells transferred from
S100-MAA immunized animals into naïve animals demonstrated over a 2 fold increase in
ALT levels compared to naïve animals immunized with S100 or normal liver T-cells.
Pathology scores were also increased in the S100-MAA immunized animals. These data
strongly suggest that immune cells were involved in the response to self-liver proteins to
initiate this autoimmune hepatitis model.
Typically, increased cytokine production has been associated with alcohol induced liver
diseases (Tiegs, 1997; Tilg and Diehl, 2000). To determine the role of cytokines in this
study whole liver homogenates were isolated from PB, S100 or S100-MAA immunized
mice and assayed for the presence of common inflammatory cytokines IL-1β, TNF-α, and
IFN-γ. Data obtained from the control unimmunized mouse livers was subtracted from S100
or S100-MAA and expressed in pg/ml. As shown in Figure 6, IL-1β was increased from
137.3 pg/ml to 343.56 pg/ml (P = 0.042) in the S100-MAA immunized mice compared to
S100 immunized mice. Also, TNF-α was increased from 150.51 pg/ml to 388.21 pg/ml (P =
0.023) over the S100 controls. IFN-γ was increased from 2370.06 pg/ml to 4830.95 pg/ml (P
= 0.024) over the S100 controls.
To further examine damage to the liver, paraffin sections were stained for smooth muscle
actin (SMA). Figure 7 shows a strong indication of SMA in the S100-MAA (panel C) liver
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sections from immunized animals. Evidence of this staining is not present in the PB (panel
A) or control S100 (panel B) liver sections. There appears to be localization around the
portal veins directly behind the endothelial lining, indicative of deposition in these sites
following activation of hepatic stellate cells. The secretion of the cytokine TGF-β is known
to start the fibrotic process in liver disease or injury. Paraffin embedded liver sections from
mice immunized with S100 or S100-MAA was stained for the presence of TGF-β using
immunohistochemical techniques. As shown in Figure 7 (panel F), there is an increase in the
staining as compared to the PB (panel D) or control S100 immunized (panel E) mouse liver
sections. Similar to that observed with SMA, this staining is strongest around the portal
veins and areas of damage, and then diffuses out in to the liver parenchyma.
Liver damage was also assessed by staining for collagen accumulation using Sirius red. As
shown in Figure 8, little to no collagen is present in the PB or S100 immunized mouse livers
following Sirius red staining. However, S100-MAA immunized mouse livers have an
abundant amount of collagen deposition between the portal tracts.
Discussion
The immune system has been suggested to play a role in the onset/progression of alcoholic
liver disease (ALD). However, the mechanism(s) as to how these immune responses are
initiated and their relationship to the development of autoimmune liver disease are still
under investigation. Studies reported in this manuscript demonstrate that aldehyde modified
proteins (alcohol-derived) can abrogate immunologic tolerance, to induce an autoimmune-
like liver disease that may be involved in the development and/or progression of ALD.
Previous studies have demonstrated that soluble exogenous proteins modified with reactive
aldehydes induce antibody and T cell responses (Abraham et al., 1995; Thiele et al., 1998;
Wuttge et al., 1999). The metabolic break down products of ethanol, (AA) (Lin et al., 1990;
Ma et al., 2005; Wehr et al., 1993) and lipid peroxidation (MDA) (Chedid et al., 1994;
Kurien and Scofield, 2008; Leitinger, 2008; Stewart et al., 2004; Wallberg et al., 2007) have
been shown to modify (adduct) proteins and initiate immune responses. We have reported
that these reactive aldehydes are capable of combining in a synergistic manner (MAA
adduct) to modify proteins and result in the immune system responding as if they were
foreign (Rolla et al., 2000; Thiele et al., 1998). Also, the combination of low concentrations
of AA and MDA on a non-self protein(s) to form MAA-protein adducts have proven to
increase; 1) Cytokine secretion, 2) Cell damage, 3) Fibronectin secretion, and 4) Antibody
and T-cell responses (Duryee et al., 2004a; Thiele et al., 2005; Thiele et al., 1998; Willis et
al., 2004; Willis et al., 2003). Importantly, the immune responses to MAA-modified proteins
have been demonstrated to occur without the use of adjuvants.
Studies reported in this manuscript sought to determine whether, immunization of mice with
MAA-modified self-proteins from syngeneic liver in the absence of adjuvant induces an
autoimmune-like hepatitis. To accomplish these studies mice were injected with low doses
of syngeneic cytosolic fractions of a liver homogenate (S100) modified in vitro with MAA
(S100-MAA). In order to assess the level of liver damage caused by immune responses, a
pathologist scored the changes in the liver of mice from each group. For example, liver
histology and AST/ALT enzyme levels were evaluated and found to be significantly
increased in the S100-MAA immunized animals when compared to controls, indicating that
tissue damage had been initiated. The fact that the pathology scores significantly correlated
with elevated hepatocellular enzyme release, strongly supports the development of
pathological changes.
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In order to determine whether the immune system was involved in these changes, the
presence of circulating antibodies specific for self-proteins was evaluated (Cook, 1998;
Czaja, 2008; Duryee et al., 2004b; Laskin et al., 1990; Thiele et al., 2004). Mice immunized
with S100-MAA had significantly increased antibody concentrations to unmodified
cytosolic liver proteins. It is important to note that these antibodies were generated in the
absence of adjuvant utilizing only 100 μg of MAA modified cytosol, as compared to other
protocols using 2.5 mg of cytosol in Freunds complete adjuvant. Additionally, these
antibodies to cytosolic proteins were found to correlate with the liver pathology scores
indicating that antibodies may be involved in the disease process. In previous studies, a dose
response was used to determine how much S100-MAA should be administered and for how
long. The use of 100 μg gave a reproducible response within a 3-4 week period. It is thought
this level was justified as others have shown in models using cytosols that lose their
immunogenicity in as little as 24-48 hours (Lohse et al., 1998). In order to modify the
cytosol with MAA, it was necessary to incubate with MDA and AA for 16 hours. More than
likely this decreases the antigenicity of the cytosol which results in the need for higher levels
of protein. Also, the use of 2 mM MDA and 1 mM AA is warranted in order to modify the
cytosol with MAA in the shortest amount of time as possible to maintain its antigenicity.
The cytosol will modify with lower concentrations of MDA and AA to the same level as
when 2 mM MDA and 1mM AA are used, but it takes 2-3 days for this too occur, which
would not allow for the retention of the cytosol antigenicity.
It is possible that cytosols are not the best materials for inducing these responses. This is,
membrane fractions or other soluble proteins may be better targets. However, this study was
designed to determine whether an autoimmune response could be generated, and most of the
traditional models of autoimmune hepatitis uses cytosols as the antigen source (Lohse et al.,
1990). Future experiments will focus on isolated macromolecules that have been shown to
be MAA-modified in vivo, and may result in the use of lower concentrations of these
modified proteins.
For example the use of serum from S100-MAA immunized mice in Western Blots using
cytosolic proteins showed reactivity to a number of proteins between 60 and 28 kd.
Preliminary protein sequencing data identified the heat shock protein binding immunophilin,
heat shock protein precursor, vascular endothelial growth factor C precursor, cytochrome
P450 3A25, and TGF-Beta receptor type II precursor as candidate self-proteins involved in
this response (data not shown). Reports show that heat shock proteins can be modified with
4-hydroxynonenal (4-HNE) or methylglyoxal, and are related to disease states in the retina
(Chen et al., 2009), ALD (Carbone et al., 2005), and liver endothelial cells in diabetes
(Schalkwijk et al., 2006). Heat shock proteins have also been shown to be involved in the
immune response by increasing the release of cytokines (Basu et al., 2000) and activation of
dendritic cells (Lumeng and Lin, 1991; Nicholls et al., 1992). Modification of these proteins
could explain how MAA-modified proteins are; internalized by dendritic cells, processed
and presented, and eventually induce antibody and T-cell responses. Therefore, multiple
self-antigens have been identified through this study that could be potential targets for the
immune system and will be the focus of future studies.
Typically, liver damage initiated by autoimmune mechanism(s) has been characterized by an
infiltration of immune cells into an area by an increase in cytokine secretion by Kupffer,
endothelial, and stellate cells (Cook, 1998; Thiele et al., 2004). Mice injected with S100-
MAA showed increases in an in vitro cellular proliferation assay when incubated with S100
alone. Involvement of reactive immune cells provides a possible mechanism by which S100
self antigens are processed and presented to stimulate T helper cell responses to aid in the
production of B cell differentiation and antibody production. Passive transfer of primed
immune cells from S100-MAA immunized animals caused an increase in ALT levels and
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pathology scores indicating these are partly responsible for the development of this liver
damage. Further studies are under investigation to evaluate the role of CD4+ (Th1, Th2,
Treg, Th17) and CD8+ T cells in this response. Preliminary dat suggest a strong role for
Th17 and Tregs in response to MAA modified proteins. Also, that dendritic cells play a
predominate role in the generation of these cells (data not shown).
Release of cytokines in the liver is an indication of a local hepatic immune responses (Cook,
1998; Thiele et al., 2004). Liver homogenates from S100 MAA immunized mice
demonstrated an increase in IL-1β, TNF-α, and IFN-γ as compared to homogenates from
S100 injected mice, all of which are pro-inflammatory cytokines responsible for the
recruitment of immune cells (CD4+, CD8+, macrophages). These cytokines have been
shown to be involved in the immunological responses following treatment of MAA-
modified proteins (Duryee et al., 2004a; Willis et al., 2004) and are directly related to what
has been observed in the progression of ALD.
As mentioned above an increase in the pathology score was observed in the livers of S100-
MAA injected mice compared to the unimmunized or S100 injected mice. Lymphocyte
clusters around the portal veins with some plasma cells were reported that formed around
the portal veins. These clusters may be explained by the ability of sinusoidal liver
endothelial cells (SECs), kupffer cells and/or stellate cells to bind MAA modified proteins,
up-regulate their adhesion molecules, and increase their secretion of cytokines following
incubation with MAA modified proteins (Sacanella and Estruch, 2003; Willis et al., 2003). It
is reasonable to hypothesize that MAA modified self-liver proteins are taken up by antigen
presenting cells through scavenger mechanisms, traffic to the lymphatic system, initiate
antibody and T-cell responses, return and bind to cells of the liver and damage the tissue
around the portal veins. Additionally, SECs can release fibronectin EIIIA in response to
MAA-modified proteins (Thiele et al., 2005). This release may initiate the fibrogenic
process by stellate cells which would release smooth muscle actin (SMA) resulting in an
increase in the wound healing type of processes. Livers from S100-MAA immunized mice
showed increased levels of SMA and collagen by immunohistochemistry strongly
supporting this scenario was initiated in these livers. Also of interest is the positive staining
for TGF-β in the S100-MAA immunized animal livers. Increases in TGF-β can activate
stellate cells to release collagen which could exacerbate the wound healing responses in the
liver and lead to fibrosis and/or cirrhosis (Tsukamoto et al., 1990). Thus, these data further
support the concept that S100-MAA injection results in the deposition of collagen between
the portal tracts and may play a role in cirrhosis.
While the underlying mechanism(s) of alcoholic liver disease is not clear, these studies
provide a potential model to evaluate how the metabolites of ethanol and lipid peroxidation
modify self-proteins to induce hepatitis. While the damage observed in these animals was
significant, they did not become morbid nor was any mortality seen following these
immunizations. This would suggest that additional factors are involved in end stage liver
failure. Therefore, more work is needed to identify cofactors such as lipopolysacharide
(LPS), genetic polymorphisms, or other toxins which result in ALD in humans. This
preclinical model offers the ability to; identify and quantify specific other cofactors, identify
and isolate specific self protein epitopes, and define specific immune pathways utilizing the
alcohol induced autoimmune hepatitis model.
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Abbreviations used in this paper
MIAH MAA Induced Autoimmune Hepatitis
MDA Malondialdehyde
AA Acetaldehyde
ALD Alcoholic Liver Disease
SMA Smooth muscle actin
S100 cytosol
MAA Malondialdehyde-acetaldehyde adduct
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H & E stains and pathology scores of livers from MIAH mice. C57/Bl6 mice were injected
with PB, 100μg S100 or 100μg S100-MAA as described in Materials and Methods. Livers
were removed, fixed, sectioned, and stained with H & E. Panel (A) PB injected mouse liver,
(B) S100 injected mouse liver, (C) S100-MAA injected mouse liver, (D) pathology scores.
H & E sections are representative of 5 slides from separate mouse livers in each group
(Magnification 200X). Slides were scored by a blinded pathologist using the Ludwig and
Batts scale of liver damage. Data are expressed as the mean ± S.E.M. of five separate
animals. Significantly different from S100 immunized control animals *P ≤ 0.04.
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AST/ALT levels in the serum from immunized mice. C57/Bl6 mice were immunized with
PB, 100μg S100 or 100μg S100-MAA as described in the Materials and Methods. Serum
was tested weekly for the presence of AST (Panel (A) and Panel (B)) ALT enzyme levels
as an indication of liver damage. Background levels of hemolysis have been subtracted out
using serum from PB injected mice. Data are expressed as the mean ± S.E.M. of five
separate animals. Significantly different from S100 immunized animals, *P ≤ 0.01 for AST
and * P ≤ 0.006 for ALT. (Panel C) Correlation of AST/ALT levels to the pathology score.
Data generated from pathology scores and AST/ALT enzymes were compared using
Pearson Product Moment Correlation test. Correlation Coefficient and P values are reported
as; AST (R=0.946, P=0.01), ALT (R=0.988, P=0.002).
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Serum antibody concentrations to S100 following immunization with MAA haptenated
S100 (S100-MAA). C57/Bl6 mice were immunized with PB, 100μg S100 or 100μg S100-
MAA as described in the Materials and Methods. (Panel A) Serum was screened against the
antigens S100 or S100-MAA followed by subtraction of the values from the serum of PB
injected mice. Data are expressed as the mean ± S.E.M. of five separate animals.
Significantly different from S100 immunized animals, *P <0.001. (Panel B) Correlation of
Anti-MAA Antibodies to Pathology scores. Data generated from antibody titers and
pathology scores were compared using Pearson Product Moment Correlation test.
Correlation Coefficient and P values are the following: (R=0.898, P=0.04).
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Western blot analysis indicating potential self proteins to antibodies from MIAH mice.
Serum collected from C57/Bl6 mice immunized with 100μg of S100-MAA was incubated
with S100 or S100-MAA antigens. Representative of five separate animals indicating bands
between 60 and 28 kd. PB and S100 immunized mice showed no reactivity and thus are not
depicted.
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T-cell proliferation in MIAH mice. Spleens from C57/Bl6 mice immunized with PB, 100μg
S100 or 100μg S100-MAA as described in the Materials and Methods were collected and
incubated with S100 or S100 MAA to determine T-cell proliferation. Data are expressed as
the mean ± S.E.M. of the stimulation index (SI) of five separate animals compared to normal
animal T-cell proliferation as indicated in the Materials and Methods section. Significantly
different from S100 immunized animals, *P ≤ 0.01.
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Release of inflammatory cytokines in liver homogenates from MIAH mice. Liver
homogenates from C57/Bl6 mice immunized with PB, 100μg S100 or 100μg S100-MAA as
described in the Materials and Methods were collected and analyzed for cytokine release.
Serum levels from PB immunized mice were subtracted from the values for S100 or S100
MAA injected mice. Cytokines evaluated were IL-1β, TNF-α, and IFN-γ. Data are expressed
as the mean ± S.E.M. of five separate animals. Significantly different from S100 immunized
animals, *P ≤ 0.001.
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Smooth muscle actin (SMA) or TGF-β staining of livers from MIAH mice. C57/Bl6 mice
were injected with PB, 100μg S100 or 100μg S100-MAA. Liver tissue was sectioned and
stained for the presence of SMA or TGF-β and evaluated using a 200x power objective.
(Panel A and D) normal mouse liver tissue. (Panel B and E) S100 immunized mice. (Panel
C and F) S100-MAA immunized mice. Data is a representative of five separate animals.
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Sirius Red staining of livers from MIAH mice. C57/Bl6 mice were injected with PB, 100μg
S100 or 100μg S100-MAA. Liver tissue was sectioned and stained for the presence collagen
using Sirius red and fast green and evaluated using a 200x objective. Data is a representative
of four separate animals.
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Table 1
Passive Transfer of T Cells From MAA-Induced Autoimmune-Like Hepatitis Mice
C57/Bl6 mice were injected with PB, 100μg S100 or 100μg S100-MAA. Spleens were extracted and
spleenocytes activated for 48 hours with Con A. Activated spleen cells were then injected into naïve mice
weekly for 3 weeks. AST and pathology scores were collected as described in Materials and Methods.
Lymphocytes injected into naïve mice from mice immunized with the following
antigens Alanine aminotransferase levels Pathology score
No immunization 40 ± 5 0
S100 control 42 ± 7 0
S100-MAA 122 ± 34 1.5 ± 0.5
Data are expressed as the mean ± S.E.M. of five separate animals. Significantly different from S100 immunized or unimmunized animals,
*
P ≤ 0.05.
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